Computed tomography imaging to quantify the area of the endocardial subvalvular apparatus in hypertrophic cardiomyopathy - Relationship to outflow tract obstruction and symptoms

J Cardiovasc Comput Tomogr. 2016 Sep-Oct;10(5):351-8. doi: 10.1016/j.jcct.2016.07.015. Epub 2016 Jul 19.

Abstract

Background: Abnormalities of the endocardial subvalvular apparatus (SVA), which includes the papillary muscles directly attached to the mitral leaflet and left ventricular apical-basal muscle bundles, are occasionally identified in hypertrophic cardiomyopathy (HCM). Their associations with left ventricular outflow tract (LVOT) obstruction are unknown.

Methods: We retrospectively reviewed cardiac computed tomography image data sets of 107 consecutive patients with HCM [56 obstructive (HOCM) and 51 non-obstructive (HNOCM)] as well as 53 controls. We evaluated anomalies of the SVA, measured the cross-sectional area of the SVA at the level of the LVOT, and subsequently assessed its correlation with the LVOT pressure gradient with and without medication.

Results: The area of the SVA was greater in HOCM than in HNOCM patients and in the control group (2.5 ± 1.3 cm(2), 1.4 ± 0.8 cm(2), and 0.9 ± 0.6 cm(2), respectively; p < 0.0001). Anomalies in the SVA were more often observed in the HOCM group than in the HNOCM patients and controls (abnormal papillary muscles, 14%, 8%, and 0%, respectively; P = 0.010; LV apical-basal muscle bundles, 73%, 65%, and 45%, respectively; P = 0.0094). Among HOCM patients, logistic regression analysis demonstrated that an SVA area of 2.2 cm(2) was an independent risk factor of residual severe LVOT obstruction (≥50 mmHg) after medication (odds ratio, 10.1; 95% confidence interval, 2.05-49.80).

Conclusion: An increased area of the endocardial subvalvular apparatus could be an independent risk factor for clinically relevant LVOT obstruction refractory to medication.

Keywords: Beta-blockers; Computed tomography; Endocardial subvalvular apparatus; Left ventricular outflow tract obstruction; Non-obstructive hypertrophic cardiomyopathy; Obstructive hypertrophic cardiomyopathy.

MeSH terms

  • Adult
  • Aged
  • Cardiomyopathy, Hypertrophic / complications
  • Cardiomyopathy, Hypertrophic / diagnostic imaging*
  • Cardiomyopathy, Hypertrophic / drug therapy
  • Cardiomyopathy, Hypertrophic / physiopathology
  • Cardiovascular Agents / therapeutic use
  • Echocardiography, Doppler
  • Endocardium / diagnostic imaging*
  • Endocardium / drug effects
  • Endocardium / physiopathology
  • Female
  • Humans
  • Linear Models
  • Logistic Models
  • Male
  • Middle Aged
  • Odds Ratio
  • Papillary Muscles / diagnostic imaging*
  • Papillary Muscles / drug effects
  • Papillary Muscles / physiopathology
  • Predictive Value of Tests
  • Reproducibility of Results
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Tomography, X-Ray Computed*
  • Ventricular Function, Left
  • Ventricular Outflow Obstruction / diagnostic imaging
  • Ventricular Outflow Obstruction / drug therapy
  • Ventricular Outflow Obstruction / etiology*
  • Ventricular Outflow Obstruction / physiopathology
  • Ventricular Pressure

Substances

  • Cardiovascular Agents